Innate Pharma S.A. ADR (IPHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 21,773 | 66,714 | 60,765 | 29,226 | 80,476 |
| Gross Profit | 21,773 | 66,714 | 60,765 | 29,226 | 80,476 |
| Operating Expenses | 77,582 | 80,426 | 121,268 | 85,808 | 151,386 |
| Operating Income | -55,809 | -13,712 | -60,503 | -56,582 | -70,909 |
| Interest Expense | 4,301 | 1,986 | 5,606 | 4,729 | 7,725 |
| Other Income | 6,578 | 7,505 | 5,030 | 7,506 | 5,546 |
| Pre-tax Income | -53,533 | -8,193 | -61,079 | -53,805 | -73,089 |
| Net Income Continuous | -53,533 | -8,193 | -61,079 | -53,805 | -73,089 |
| Net Income Discontinuous | N/A | N/A | -138 | -8,673 | N/A |
| Net Income | $-53,533 | $-8,193 | $-61,217 | $-62,478 | $-73,089 |
| EPS Basic Total Ops | -0.66 | -0.10 | -0.77 | -0.78 | -0.93 |
| EPS Basic Continuous Ops | -0.66 | -0.10 | -0.77 | -0.68 | -0.93 |
| EPS Basic Discontinuous Ops | N/A | N/A | 0.00 | -0.11 | N/A |
| EPS Diluted Total Ops | -0.66 | -0.10 | -0.77 | -0.78 | -0.93 |
| EPS Diluted Continuous Ops | -0.66 | -0.10 | -0.77 | -0.68 | -0.93 |
| EPS Diluted Discontinuous Ops | N/A | N/A | 0.00 | -0.11 | N/A |
| EPS Diluted Before Non-Recurring Items | -0.66 | -0.10 | -0.23 | -0.67 | -0.30 |
| EBITDA(a) | $-53,652 | $-8,202 | $-12,664 | $-51,144 | $-6,030 |